Pseudoxanthoma elasticum is a progressive genetic disorder that affects elastic tissue throughout the body, particularly in the skin, eyes, and blood vessels, leading to characteristic yellowish skin changes and potentially serious vision and cardiovascular complications.
Introduction: When Should You Seek Diagnostic Testing?
Recognizing when to pursue diagnostic evaluation for pseudoxanthoma elasticum can be challenging, especially since the condition often begins quietly in childhood or adolescence. Anyone who notices unusual changes in their skin, particularly small yellowish bumps that appear on the neck, underarms, or other areas where skin folds when joints bend, should consider seeking medical assessment. These skin changes might look somewhat like a “plucked chicken” or have a textured, cobblestone appearance that sets them apart from normal skin.[1]
Diagnostic evaluation becomes particularly important when these skin findings coincide with any changes in vision or if there is a family history of similar symptoms. Since pseudoxanthoma elasticum is an inherited condition, having a sibling or other close relative with diagnosed PXE should prompt earlier screening. Women appear to be diagnosed with this condition approximately twice as often as men, though the reason for this difference remains unclear. The condition affects people of all ethnic backgrounds and races.[3]
Individuals who discover unusual retinal findings during a routine eye examination, such as the distinctive patterns called angioid streaks, should pursue comprehensive diagnostic testing even if they have not yet noticed skin changes. Sometimes the eye manifestations appear before skin lesions become obvious, or skin changes may be subtle enough that they go unnoticed by the affected person. Early diagnosis allows for proper monitoring and management strategies that can help preserve vision and cardiovascular health over time.[2]
Classic Diagnostic Methods
Clinical Examination and Skin Assessment
The diagnostic journey for pseudoxanthoma elasticum typically begins with a thorough clinical examination focused on characteristic skin manifestations. Healthcare providers look for distinctive yellowish papules, which are small raised bumps ranging from about one to five millimeters in diameter. These lesions most commonly appear on the sides and back of the neck, in the armpits, at the inner elbows, behind the knees, and in the groin area. The bumps often start out individually scattered but gradually coalesce into larger patches or plaques that give the skin a unique cobblestone texture.[3]
As the condition progresses, the affected skin may become noticeably soft, loose, and slightly wrinkled, creating redundant folds particularly visible in the neck area. Some individuals develop prominent horizontal creases across the chin, which can appear at a relatively young age. Although less common, the oral mucosa inside the mouth, as well as vaginal and rectal tissues, may also show similar changes. The examining physician will carefully document the distribution, appearance, and extent of these skin changes.[7]
Skin Biopsy and Histological Examination
When skin findings suggest pseudoxanthoma elasticum but are not definitive, or when eye abnormalities are present without obvious skin changes, a skin biopsy becomes essential for confirming the diagnosis. This procedure involves removing a small sample of skin tissue, typically from an affected area such as the neck or armpit, for detailed examination under a microscope. The biopsy specimen undergoes special staining techniques, particularly the von Kossa stain or similar methods that specifically highlight calcium deposits.[2]
Under microscopic examination, tissue from individuals with PXE reveals distinctive changes in the elastic fibers, which are components of connective tissue that normally provide skin with its flexibility and ability to stretch. In PXE, these elastic fibers in the middle and deeper layers of the skin appear shortened, fragmented, and clumped together. Most importantly, they show abnormal deposits of calcium and other minerals, a process called calcification or mineralization. This calcification causes the elastic fibers to lose their normal function and eventually break apart.[6]
The highest diagnostic yield comes from biopsying an actual papule rather than normal-appearing skin, though even skin without visible lesions may sometimes show these characteristic microscopic changes. When the biopsy clearly demonstrates calcified, fragmented elastic fibers in the proper location within the skin layers, it provides strong confirmation of the diagnosis.[13]
Comprehensive Eye Examination
Eye examination by a specialist in retinal diseases forms another crucial component of diagnosing pseudoxanthoma elasticum. The ophthalmologist uses specialized instruments to examine the back of the eye, looking for several distinctive features. The earliest finding, often visible in childhood or early adolescence, is called peau d’orange, which is French for “skin of an orange.” This refers to a mottled, yellowish appearance of the retina, particularly in the temporal region, that resembles the surface texture of an orange peel.[3]
The hallmark eye finding in PXE is the presence of angioid streaks, which are narrow, irregular, dark reddish-brown or grayish lines that radiate outward from the optic nerve head like spokes on a wheel or form rings around it. These streaks represent tiny cracks or breaks in Bruch’s membrane, which is a thin but crucial layer of tissue located beneath the retina. Bruch’s membrane is rich in elastic fibers, and when these fibers become calcified and brittle due to PXE, the membrane develops these characteristic breaks.[2]
Another diagnostic feature unique to PXE is the presence of “comet tails,” which are small areas of tissue deterioration in the peripheral regions of the retina. These comet tail lesions are considered pathognomonic for PXE, meaning their presence is so characteristic that they essentially confirm the diagnosis. The ophthalmologist may also use specialized photography or imaging techniques such as fluorescein angiography, which involves injecting a dye into the bloodstream and photographing how it flows through the retinal blood vessels, to better visualize these abnormalities.[3]
It bears emphasizing that neither peau d’orange nor angioid streaks themselves cause vision problems. However, their presence indicates underlying changes in the eye structure that create risk for future complications. Regular monitoring by an experienced eye care professional familiar with PXE becomes essential once these findings are identified.[5]
Genetic Testing
Genetic testing provides definitive molecular confirmation of pseudoxanthoma elasticum by identifying mutations in the ABCC6 gene, which is located on chromosome 16. This gene provides instructions for making a protein that functions as a transporter, moving certain substances across cell membranes, particularly in liver and kidney cells. Although the exact substances transported remain under investigation, the lack of functional ABCC6 protein leads to the characteristic mineralization seen throughout the body in PXE.[1]
More than 300 different sequence variants or mutations in the ABCC6 gene have been identified in individuals with PXE. Most of these are missense mutations (where one building block of the protein is substituted for another) or nonsense mutations (which create premature stop signals that truncate the protein). Interestingly, just two common variants account for approximately half of all PXE cases, though the wide variety of possible mutations means each affected individual or family may have their own unique combination.[6]
Genetic testing typically requires a blood sample, from which DNA is extracted and analyzed to search for mutations in the ABCC6 gene. Since PXE follows an autosomal recessive inheritance pattern, affected individuals must inherit two copies of the mutated gene—one from each parent. Parents who each carry one mutated copy typically show no symptoms themselves but have a 25 percent chance with each pregnancy of having a child with PXE. Genetic testing can identify not only affected individuals but also carriers within a family, which becomes valuable information for family planning and genetic counseling purposes.[2]
Additional Diagnostic Investigations
Because pseudoxanthoma elasticum affects multiple body systems beyond just the skin and eyes, comprehensive diagnosis often includes additional testing to assess cardiovascular health and detect any complications. Blood tests typically include a complete lipid panel measuring cholesterol levels, including HDL (high-density lipoprotein), LDL (low-density lipoprotein), VLDL (very low-density lipoprotein), and triglycerides. These tests help identify elevated blood fat levels that could compound cardiovascular risk. Other blood markers that may be measured include lipoprotein(a), homocysteine, and C-reactive protein, all of which provide information about inflammation and cardiovascular disease risk.[8]
Imaging studies help evaluate the blood vessels and heart. Echocardiography, which uses ultrasound to create moving pictures of the heart, can detect valve abnormalities such as mitral valve prolapse and assess overall heart function. Some centers recommend this test annually for individuals with PXE. Stress testing evaluates how the heart performs during physical exertion. Blood pressure monitoring, sometimes including 24-hour ambulatory monitoring, helps detect hypertension that may result from calcified arteries. Advanced imaging such as CT scanning of the coronary arteries can directly visualize calcium deposits in heart vessels.[4]
If gastrointestinal symptoms occur, a complete blood count checks for anemia resulting from potential internal bleeding. Specialized tests examining the stomach and intestines may be performed if bleeding is suspected, though gastrointestinal complications are relatively uncommon in PXE.[12]
Diagnostics for Clinical Trial Qualification
When individuals with pseudoxanthoma elasticum consider participating in clinical research studies or trials investigating potential new treatments, they typically undergo additional diagnostic evaluations beyond standard clinical care. These specialized assessments serve multiple purposes: they help researchers precisely characterize disease severity, establish baseline measurements against which treatment effects can be compared, and ensure that enrolled participants meet specific criteria that make the study scientifically valid and safe.
Confirming Eligibility Through Genetic Analysis
Clinical trials for PXE usually require definitive genetic confirmation through identification of biallelic ABCC6 pathogenic variants, meaning that both copies of the ABCC6 gene must carry disease-causing mutations. This molecular confirmation ensures that all study participants truly have PXE rather than another condition that might appear similar. Research-grade genetic testing may be more extensive than clinical testing, sometimes including full sequencing of all 31 exons (protein-coding regions) of the ABCC6 gene to identify even rare or previously undescribed mutations.[2]
Some clinical trials may specifically enroll only individuals with certain types of ABCC6 mutations. For example, studies have found that people with mixed genotypes (combinations of different mutation types) may have more favorable clinical outcomes compared to those with two truncating mutations or two non-truncating mutations. Trials testing interventions aimed at specific molecular mechanisms might require participants to have particular mutation profiles.[6]
Detailed Retinal Assessment
For clinical trials focused on preventing or treating the vision complications of PXE, extensive eye examinations establish baseline ocular status. Beyond standard eye exams, these may include high-resolution retinal photography to document the exact appearance and extent of angioid streaks. Optical coherence tomography (OCT), an imaging technique that creates cross-sectional pictures of the retina’s layers, can detect subtle fluid accumulation or structural changes not visible on standard examination.[2]
Fluorescein angiography becomes particularly important in research settings to detect early choroidal neovascularization (CNV), which occurs when abnormal blood vessels begin growing through the breaks in Bruch’s membrane. This complication represents a major cause of vision loss in PXE, and trials testing preventive strategies need to identify participants before CNV develops or in its earliest stages. Detailed visual acuity testing using standardized charts measures precisely how well participants can see, providing objective baseline data for comparison after treatment.[4]
Cardiovascular Imaging and Function Tests
Clinical trials addressing cardiovascular aspects of PXE require detailed assessment of blood vessel calcification and heart function. Advanced imaging techniques can quantify the amount of calcium deposited in arteries. Peripheral arterial calcification mass scores measure mineralization in leg arteries, while coronary artery calcium scoring assesses heart vessel involvement. These measurements provide objective data about disease burden that can be tracked over time to evaluate whether experimental treatments slow progression.[6]
Functional cardiovascular testing might include measurements of blood flow to the extremities using specialized ultrasound techniques. Tests that evaluate how well patients can walk before experiencing leg cramping (claudication) provide functional assessments of peripheral artery disease. Comprehensive evaluation of blood pressure control, including home monitoring or 24-hour ambulatory recordings, helps identify hypertension that may be related to arterial calcification. Blood tests measuring kidney function ensure that complications have not yet affected these organs.[4]
Skin Documentation
Research studies often include standardized photographic documentation of skin lesions, measuring the size and distribution of affected areas. While skin manifestations rarely cause medical problems beyond cosmetic concerns, they provide visible markers of disease presence and severity. Some trials investigating treatments aimed at reducing mineralization might use skin biopsy to measure changes in calcium deposition at the tissue level before and after treatment.[15]
Laboratory Markers of Mineral Metabolism
Emerging research suggests that PXE represents a metabolic disorder involving abnormal mineral balance rather than simply a structural defect in elastic fibers. Clinical trials exploring this metabolic aspect may measure blood levels of substances involved in calcium and phosphate regulation. Inorganic pyrophosphate (PPi), a natural inhibitor of mineralization, is often deficient in individuals with PXE. Measuring PPi levels and the ratio of PPi to inorganic phosphate provides insight into the metabolic abnormalities underlying the disease. Some research protocols also measure related factors such as adenosine triphosphate (ATP) breakdown products.[15]
Quality of Life Assessments
Beyond objective medical measurements, many clinical trials include standardized questionnaires assessing how PXE affects daily life, emotional wellbeing, and functional capabilities. These patient-reported outcomes capture aspects of disease burden that laboratory tests and imaging cannot measure, such as anxiety about vision loss, limitations in physical activities, or concerns about appearance. Such assessments help researchers understand whether new treatments improve not just measurable parameters but also how people actually feel and function in their everyday lives.[10]
